VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | The promise of combining navitoclax and ruxolitinib in MF

In this video, Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the promise of combining navitoclax with ruxolitinib for the treatment of myelofibrosis (MF), and important factors to consider when selecting patients for this combination. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter